77 episodes

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

JAMA Oncology Author Interviews JAMA Network

    • Medicine
    • 3.6 • 7 Ratings

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

    Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC

    Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC

    Interview with Charu Aggarwal, MD, and Lova Sun, MD, authors of Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

    • 15 min
    Chronic Toxic Effects Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma

    Chronic Toxic Effects Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma

    Interview with Douglas B. Johnson, MD, author of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

    • 17 min
    Anti–PD-1 Immunotherapy in Microsatellite-Stable Tumors With 10 or More Mutations per Megabase

    Anti–PD-1 Immunotherapy in Microsatellite-Stable Tumors With 10 or More Mutations per Megabase

    Interview with Luc GT Morris, MD MSc, author of Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase

    • 29 min
    Virtual Care Across a Tertiary Cancer Center During COVID-19

    Virtual Care Across a Tertiary Cancer Center During COVID-19

    Interview with Alejandro Berlin, MD, MSc, author of Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19

    • 23 min
    Osteonecrosis of the Jaw in Patients Receiving Zoledronic Acid for Bone Metastases

    Osteonecrosis of the Jaw in Patients Receiving Zoledronic Acid for Bone Metastases

    Interview with Catherine Van Poznak, MD, author of Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer

    • 13 min
    Discontinuation of Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

    Discontinuation of Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

    Interview with Ehab Atallah, MD, author of Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial

    • 15 min

Customer Reviews

3.6 out of 5
7 Ratings

7 Ratings

HamletDemetrius ,

Good podcast

Love these JAMA podcasts, I work in oncology and this helps keep me up to date.

Top Podcasts In Medicine

Listeners Also Subscribed To

More by JAMA Network